$22.87
-1.80 (-7.30%)
Open$26.01
Previous Close$24.67
Day High$26.99
Day Low$22.41
52W High$36.76
52W Low$6.33
Volume—
Avg Volume116.7K
Market Cap19.50M
P/E Ratio—
EPS$-142.73
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+26.1% upside
Current
$22.87
$22.87
Target
$28.84
$28.84
$22.09
$28.84 avg
$40.88
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 6.00M | 5.90M | 5.57M |
| Net Income | -817,172 | -706,875 | -767,435 |
| Profit Margin | -13.6% | -12.0% | -13.8% |
| EBITDA | -1,135,758 | -954,399 | -978,652 |
| Free Cash Flow | -597,971 | -436,320 | -559,358 |
| Rev Growth | +2.3% | +18.9% | +16.5% |
| Debt/Equity | 0.18 | 0.16 | 0.22 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $254.31 | +0.38% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $360.55 | +0.62% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.33 | -1.21% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $499.65 | +1.69% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $631.81 | -0.17% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $293.52 | +0.74% | 69.3 | 39.97B |